CD38 and plasma cell myeloma: Previously, we reviewed the literature regarding the total therapy strategy, including PIs, IMiDs, anti-CD38 MoAb, and ASCT, which not only induce a therapeutic effect on the myeloma cells but also improve the bone marrow microenvironment, including the enhancement of anti-myeloma immunological activity and the suppression of inhibitory anti-myeloma immunological effects [2,3].